References
- Angus, D. C., van der Poll, T. (2013). Severe sepsis and septic shock. New Engl. J. Med., 369, 840–851.
- Angus, D. C. (2010). The lingering consequences of sepsis: A hidden public health disaster? JAMA,304 (16), 1833–1834.
- Annane, D., Bellissant, E., Cavaillon, J. M. (2005). Septic shock. Lancet, 36, 63–78.
- Anonymous (2018a). Nomenclature for factors of the HLA system. Available at: http://hla.alleles.org/nomenclature/index.html (accessed 07.01.2019).
- Anonymous (2016). QIAamp DNA Mini and Blood Mini Handbook – 372 EN. Avalaible at: http://www.qiagen.com/ (accessed 09.01.2019).
- Anonymous (2018b). Handbook – HLA -DRB1; DQA1; DQB1 kits EN. Avalaible at: http://www.dna-technology.ru/ (accessed 09.01.2019).
- Blackwell, J. M., Jamieson, S. E., Burgner, D. (2009). HLA and infectious diseases. Clin. Microbiol. Rev.,22, 370–385.
- Burgner, D., Jamieson, S. E., Blackwell, J. M. (2006). Genetic susceptibility to infectious diseases: Big is beautiful, but will bigger be even better? Lancet Infect Dis., 6 (10), 653–663.
- Burton, P. R., Tobin, M. D., Hopper, J. L. (2005). Key concepts in genetic epidemiology. Lancet,366, 941–951.
- Cajander, S., Tina, E., Bäckman, A., Magnuson, A., Strålin, K., Söderquist, B., Källman, J. (2016). Quantitative real-time polymerase chain reaction measurement of HLA-DRA gene expression in whole blood is highly reproducible and shows changes that reflect dynamic shifts in monocyte surface HLA-DR expression during the course of sepsis. PLoS One, 11 (5), e0154690.
- Cajander, S., Bäckman, A., Tina, E., Stralin, K., Bo Soderquist, Kallman, J. (2013). Preliminary results in quantitation of HLA-DRA by real-time PCR: A promising approach to identify immunosuppression in sepsis. Crit. Care,17 (5), R223.
- Cazalis, M. A., Friggeri, A., Cavé, L., Demaret, J., Barbalat, V., Cerrato, E., Lepape, A., Pachot, A., Monneret, G., Venet, F. (2013). Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock. Crit. Care,17 (6), R287.
- Cazalis, M. A., Lepape, A., Venet, F., Frager, F., Mougin, B., Vallin, H., Paye, M., Pachot, A., Monneret, G. (2014). Early and dynamic changes in gene expression in septic shock patients: A genome-wide approach. Intensive Care Med. Exp., 2 (1), 20.
- Choi, N. M., Majumder, P., Boss, J. M. (2011). Regulation of major histocompatibility complex class II genes. Curr. Opin. Immunol., 23 (1), 81–87.
- Eglite, J., Hagina, E., Pavare, J., Grope, I., Gardovska, D., Sochnevs, A. (2010). Polymorphisms of HLA-DRB1* locus and the associations with HMGB1 protein in children with SIRS and sepsis. RSU Research Articles in Medicine & Pharmacy. Rīga Stradiņš University, Rīga, pp. 14–18.
- Fisher, C. J. Jr., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M., Benjamin, E. (1996). Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. New Engl. J. Med., 334 (26), 1697–1702.
- Hanna, S., Etzioni, A. (2014). MHC class I and II deficiencies. J. Allergy Clin. Immunol., 134, 269–275.
- Horton, R., Gibson, R., Coggill, P., Miretti, M., Allcock, R. J., Almeida, J., Forbes, S., Gilbert, J. G., Halls, K., Harrow, J. L., Hart, E., Howe, K., Jackson, D. K., Palmer, S., Roberts, A. N., Sims, S., Stewart, C. A., Traherne, J. A., Trevanion, S., Wilming, L., Rogers, J., de Jong P. J., Elliott, J. F., Sawcer, S., Todd, J. A., Trowsdale, J., Beck, S. (2008). Variation analysis and gene annotation of eight MHC haplotypes: The MHC Haplotype Project. Immunogenetics,60 (1), 1–18.
- Hotchkiss, R. S., Karl, I. E. (2003). The pathophysiology and treatment of sepsis. New Engl. J. Med., 17, 138–150.
- Jabandziev, P., Smerek, M., Michalek, J., Fedora, M., Kosinova, L., Hubacek, J. A., Michalek, J. (2014). Multiple gene-to-gene interactions in children with sepsis: A combination of five gene variants predicts outcome of life-threatening sepsis. Crit. Care., 18 (1), R1.
- Kumpf, O., Schumann, R. R. (2008). Genetic influence on bloodstream infections and Sepsis. Int. J. Antimicr. Agents,32, S44–S50.
- Kuniholm, M. H., Xie, X., Anastos, K., Xue, X., Reimers, L., French, A. L., Gange, S. J., Kassaye, S. G., Kovacs, A., Wang. T., Aouizerat, B. E., Strickler, H. D. (2016). Human leucocyte antigen class I and II imputation in a multiracial population. Int. J. Immunogenet.,43 (6), 369–375.
- Landelle, C., Lepape, A., Voirin, N., Tognet, E., Venet, F., Bohé, J., Vanhems, P., Monneret, G. (2010). Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Int. Care Med., 36 (11), 1859–1866.
- Leentjens, J., Kox, M., van der Hoeven, J.G., Netea, M.G., Pickkers, P. (2013). Immunotherapy for the adjunctive treatment of sepsis: From immunosuppression to immunostimulation. Time for a paradigm change? Amer. J. Respir. Crit. Care Med., 187 (12), 1287–1293.
- Levy, M. M., Dellinger, R. P., Townsend, S. R., Linde-Zwirble, W. T., Marshall, J. C., Bion, J., Schorr, C., Artigas, A., Ramsay, G., Beale, R., Parker, M. M., Gerlach, H., Reinhart, K., Silva, E., Harvey, M., Regan, S., Angus, D. C. (2010). The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med., 36 (2), 222–231.
- Mato, A. R., Fuchs, B. D., Heitjan, D. F., Mick, R., Halpern, S. D., Shah, P. D., Jacobs, S., Olson, E., Schuster, S. J., Ujjani, C., Chong, E. A., Loren, A. W., Luger, S. M. (2009). Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol. Ther., 8 (12), 1095–1100.
- Michalek, J., Svetlikova, P., Fedora, M., Klimovic, M., Klapacova, L., Bartosova, D., Hrstkova, H., Hubacek, J. A. (2007). Interleukin-6 gene variants and the risk of sepsis development in children. Human Immunol., 68 (9), 756–760.
- Monneret, G., Venet, F. (2015). Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytometry B Clin. Cytom.,90 (4), 376–386.
- Monneret, G., Venet, F., Pachot, A., Lepape, A. (2008). Monitoring immune dysfunctions in the septic patient: A new skin for the old ceremony. Mol. Med., 17, 64–78.
- Hutchins, N. A., Unsinger, J., Hotchkiss, R. S., Ayala, A. (2014). The new normal: Immuno-modulatory agents against sepsis immune suppression. Trends Mol. Med., 20 (4), 224–233.
- Otto, G. P., Sossdorf, M., Claus, R. A., Rödel, J., Menge, K., Reinhart, K., Bauer, M., Riedemann, N. C. (2011). The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care., 15 (4), R183.
- Pachot, A., Monneret, G., Brion, A., Venet, F., Bohé, J., Bienvenu, J., Mougin, B., Lepape, A. (2005). Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit. Care Med.,33 (1), 31–38.
- Payen, D., Monneret, G., Hotchkiss, R. (2013). Immunotherapy—a potential new way forward in the treatment of sepsis. Crit. Care,17, 118.
- Shimokawa, P. T., Targa, L. S., Yamamoto, L., Rodrigues, J. C., Kanunfre, K. A., Okay, T. S. (2016). HLA-DQA1/B1 alleles as putative susceptibility markers in congenital toxoplasmosis. Virulence, 7 (4), 456–464.
- Watson, R. S., Carcillo, J. A., Linde-Zwirble, W. T., Clermont, G., Lidicker, J., Angus, D. C. (2003). The epidemiology of severe sepsis in children in the United States. Amer. J. Respir. Crit. Care Med., 167, 695–701.